Cargando…
Analysis of CRISPR‐Cas9 screens identifies genetic dependencies in melanoma
Targeting the MAPK signaling pathway has transformed the treatment of metastatic melanoma. CRISPR‐Cas9 genetic screens provide a genome‐wide approach to uncover novel genetic dependencies that might serve as therapeutic targets. Here, we analyzed recently reported CRISPR‐Cas9 screens comparing data...
Autores principales: | Christodoulou, Eirini, Rashid, Mamunur, Pacini, Clare, Droop, Alastair, Robertson, Holly, van Groningen, Tim, Teunisse, Amina F. A. S., Iorio, Francesco, Jochemsen, Aart G., Adams, David J., van Doorn, Remco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818247/ https://www.ncbi.nlm.nih.gov/pubmed/32767816 http://dx.doi.org/10.1111/pcmr.12919 |
Ejemplares similares
-
Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen
por: Glinkina, Kseniya, et al.
Publicado: (2022) -
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma
por: Glinkina, Kseniya A., et al.
Publicado: (2023) -
Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma
por: Heijkants, Renier, et al.
Publicado: (2017) -
MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells
por: Heijkants, Renier C., et al.
Publicado: (2022) -
Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
por: Glinkina, Kseniya, et al.
Publicado: (2022)